These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

817 related items for PubMed ID: 17452372

  • 1. Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats.
    Carta M, Carlsson T, Kirik D, Björklund A.
    Brain; 2007 Jul; 130(Pt 7):1819-33. PubMed ID: 17452372
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Impact of grafted serotonin and dopamine neurons on development of L-DOPA-induced dyskinesias in parkinsonian rats is determined by the extent of dopamine neuron degeneration.
    Carlsson T, Carta M, Muñoz A, Mattsson B, Winkler C, Kirik D, Björklund A.
    Brain; 2009 Feb; 132(Pt 2):319-35. PubMed ID: 19039008
    [Abstract] [Full Text] [Related]

  • 4. Serotonin neuron-dependent and -independent reduction of dyskinesia by 5-HT1A and 5-HT1B receptor agonists in the rat Parkinson model.
    Muñoz A, Carlsson T, Tronci E, Kirik D, Björklund A, Carta M.
    Exp Neurol; 2009 Sep; 219(1):298-307. PubMed ID: 19500572
    [Abstract] [Full Text] [Related]

  • 5. MDMA and fenfluramine reduce L-DOPA-induced dyskinesia via indirect 5-HT1A receptor stimulation.
    Bishop C, Taylor JL, Kuhn DM, Eskow KL, Park JY, Walker PD.
    Eur J Neurosci; 2006 May; 23(10):2669-76. PubMed ID: 16817869
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. L-DOPA-induced dopamine efflux in the striatum and the substantia nigra in a rat model of Parkinson's disease: temporal and quantitative relationship to the expression of dyskinesia.
    Lindgren HS, Andersson DR, Lagerkvist S, Nissbrandt H, Cenci MA.
    J Neurochem; 2010 Mar; 112(6):1465-76. PubMed ID: 20050978
    [Abstract] [Full Text] [Related]

  • 8. Impact of dopamine to serotonin cell ratio in transplants on behavioral recovery and L-DOPA-induced dyskinesia.
    García J, Carlsson T, Döbrössy M, Nikkhah G, Winkler C.
    Neurobiol Dis; 2011 Sep; 43(3):576-87. PubMed ID: 21600983
    [Abstract] [Full Text] [Related]

  • 9. Amphetamine-induced abnormal movements occur independently of both transplant- and host-derived serotonin innervation following neural grafting in a rat model of Parkinson's disease.
    Lane EL, Brundin P, Cenci MA.
    Neurobiol Dis; 2009 Jul; 35(1):42-51. PubMed ID: 19361557
    [Abstract] [Full Text] [Related]

  • 10. Characterization of enhanced behavioral responses to L-DOPA following repeated administration in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
    Henry B, Crossman AR, Brotchie JM.
    Exp Neurol; 1998 Jun; 151(2):334-42. PubMed ID: 9628768
    [Abstract] [Full Text] [Related]

  • 11. NLX-112, a novel 5-HT1A receptor agonist for the treatment of L-DOPA-induced dyskinesia: Behavioral and neurochemical profile in rat.
    Iderberg H, McCreary AC, Varney MA, Kleven MS, Koek W, Bardin L, Depoortère R, Cenci MA, Newman-Tancredi A.
    Exp Neurol; 2015 Sep; 271():335-50. PubMed ID: 26037043
    [Abstract] [Full Text] [Related]

  • 12. The differential effects of 5-HT(1A) receptor stimulation on dopamine receptor-mediated abnormal involuntary movements and rotations in the primed hemiparkinsonian rat.
    Dupre KB, Eskow KL, Negron G, Bishop C.
    Brain Res; 2007 Jul 16; 1158():135-43. PubMed ID: 17553470
    [Abstract] [Full Text] [Related]

  • 13. Serotonin 1B receptor stimulation reduces D1 receptor agonist-induced dyskinesia.
    Jaunarajs KL, Dupre KB, Steiniger A, Klioueva A, Moore A, Kelly C, Bishop C.
    Neuroreport; 2009 Sep 23; 20(14):1265-9. PubMed ID: 19633584
    [Abstract] [Full Text] [Related]

  • 14. Activity of serotonin 5-HT(1A) receptor 'biased agonists' in rat models of Parkinson's disease and L-DOPA-induced dyskinesia.
    Iderberg H, McCreary AC, Varney MA, Cenci MA, Newman-Tancredi A.
    Neuropharmacology; 2015 Jun 23; 93():52-67. PubMed ID: 25645393
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Chronic SKF83959 induced less severe dyskinesia and attenuated L-DOPA-induced dyskinesia in 6-OHDA-lesioned rat model of Parkinson's disease.
    Zhang H, Ma L, Wang F, Chen J, Zhen X.
    Neuropharmacology; 2007 Jul 23; 53(1):125-33. PubMed ID: 17553535
    [Abstract] [Full Text] [Related]

  • 18. 5-Hydroxy-tryptophan for the treatment of L-DOPA-induced dyskinesia in the rat Parkinson's disease model.
    Tronci E, Lisci C, Stancampiano R, Fidalgo C, Collu M, Devoto P, Carta M.
    Neurobiol Dis; 2013 Dec 23; 60():108-14. PubMed ID: 24004632
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. [Tandospirone citrate, a selective 5-HT1A agonist, alleviates L-DOPA-induced dyskinesia in patients with Parkinson's disease].
    Kannari K, Kurahashi K, Tomiyama M, Maeda T, Arai A, Baba M, Suda T, Matsunaga M.
    No To Shinkei; 2002 Feb 23; 54(2):133-7. PubMed ID: 11889759
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 41.